{
    "organizations": [],
    "uuid": "522a2d60b9440a6102392d6e0bbc0ea7a6d3d7b1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mercks-keytruda-succeeds-in-squamo/brief-mercks-keytruda-succeeds-in-squamous-non-small-cell-lung-cancer-study-idUSASC0A3CD",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck's Keytruda succeeds in squamous non-small cell lung cancer study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Merck & Co Inc:\n* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT FOR SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN PIVOTAL PHASE 3 KEYNOTE-407 TRIAL\n* MERCK & CO INC - KEYTRUDA HAS NOW DEMONSTRATED AN IMPROVED SURVIVAL BENEFIT IN ADVANCED NSCLC IN FIVE PHASE 3 TRIALS\n* MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED IN LUNG CANCER\n* MERCK & CO - BASED ON AN INTERIM ANALYSIS TREATMENT WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY RESULTED IN LONGER OS & PFS THAN CHEMOTHERAPY ALONE\n* MERCK & CO - SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY\n* MERCK & CO INC - KEYTRUDA COMBINATION MET DUAL PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) IN STUDY\n* MERCK & CO INC - PRESENTING OVERALL SURVIVAL & PROGRESSION-FREE SURVIVAL FINDINGS FROM KEYNOTE-407 AT 2018 ASCO ANNUAL MEETING Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T18:57:00.000+03:00",
    "crawled": "2018-05-24T20:45:11.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "pembrolizumab",
        "significantly",
        "improved",
        "overall",
        "survival",
        "survival",
        "treatment",
        "squamous",
        "cell",
        "lung",
        "cancer",
        "nsclc",
        "pivotal",
        "phase",
        "trial",
        "merck",
        "co",
        "inc",
        "keytruda",
        "demonstrated",
        "improved",
        "survival",
        "benefit",
        "advanced",
        "nsclc",
        "five",
        "phase",
        "trial",
        "merck",
        "co",
        "inc",
        "safety",
        "profile",
        "keytruda",
        "combination",
        "consistent",
        "previously",
        "observed",
        "lung",
        "cancer",
        "merck",
        "co",
        "based",
        "interim",
        "analysis",
        "treatment",
        "keytruda",
        "combination",
        "chemotherapy",
        "resulted",
        "longer",
        "o",
        "pfs",
        "chemotherapy",
        "alone",
        "merck",
        "co",
        "submitted",
        "sbla",
        "keytruda",
        "combination",
        "fda",
        "new",
        "data",
        "shared",
        "agency",
        "merck",
        "co",
        "inc",
        "keytruda",
        "combination",
        "met",
        "dual",
        "primary",
        "endpoint",
        "overall",
        "survival",
        "o",
        "survival",
        "pfs",
        "study",
        "merck",
        "co",
        "inc",
        "presenting",
        "overall",
        "survival",
        "survival",
        "finding",
        "asco",
        "annual",
        "meeting",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}